Bray June 4

What Happened
Bray June, a director of Quince Therapeutics (QNCX), received a grant of 18,724 shares (reported as a derivative award) on January 2, 2026. The grant price is listed as $0.00 (no cash paid); this was an award/option grant rather than a purchase or sale. The Reporting Person elected to receive these stock options in lieu of the 2026 annual director cash retainer.

Key Details

• Transaction date: 2026-01-02 (reported on Form 4 filed 2026-01-21). Filing appears to be later than the typical 2-business-day Form 4 window.
• Transaction type/code: A — Award/Grant (derivative).
• Shares/options granted: 18,724; reported price $0.00 (no cash exchanged).
• Vesting: Per footnote, vesting in equal quarterly installments over a one-year period.
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Footnote: Grant was elected in lieu of the director cash retainer under the issuer’s Outside Director Compensation Policy.

Context: This was an equity compensation grant to a director (routine for non-employee directors) rather than a market purchase or sale. Derivative awards like this create potential future dilution and align directors’ interests with shareholders as they vest, but they do not represent an immediate cash investment or sale.